Phase I Safety and Immunogenicity Trial of an Investigational RNActive Rabies Vaccine (CV7201) in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2018
Price : $35 *
At a glance
- Drugs Nadorameran (Primary) ; Nadorameran (Primary)
- Indications Rabies
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors CureVac
- 25 Oct 2018 Status changed from active, no longer recruiting to completed.
- 11 Jan 2017 Interim results published in a CureVac media release.
- 11 Jan 2017 Interim results presented at the 35th Annual J.P. Morgan Healthcare Conference, as per a CureVac media release.